Arrowhead Pharmaceuticals Inc Revenue Growth Rates (ARWR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Arrowhead Pharmaceuticals Inc   (NASDAQ: ARWR)
 

ARWR's Revenue Growth by Quarter and Year

Arrowhead Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARWR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter September -
3rd Quarter June 75.25
2nd Quarter March 73.74
1st Quarter December 264.03
FY 413.02

ARWRs Annual Revenue
Arrowhead Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 829.45 millions
Arrowhead Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 3.55 millions
Arrowhead Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 240.74 millions
Arrowhead Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 243.23 millions
Arrowhead Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 138.29 millions




ARWR Revenue third quarter 2026 Y/Y Growth Comment
Arrowhead Pharmaceuticals Inc reported Revenue surge of 170.99% year on year in the third quarter 2026, to $ 75.25 millions, this is lower than Arrowhead Pharmaceuticals Inc 's recent average Revenue surge of 1034.93%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 55 other companies have achieved higher Revenue growth. While Arrowhead Pharmaceuticals Inc ' s Revenue doubling of 170.99% ranks overall at the positon no. 493 in the third quarter 2026.


ARWR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter September - - - -49.02 %
3rd Quarter June 170.99 % - - -51.16 %
2nd Quarter March -86.41 % - - -3.65 %
1st Quarter December 10461.2 % -29.58 % -94.32 % 127.95 %
FY   - 23264.79 % -98.53 % -

Financial Statements
Arrowhead Pharmaceuticals Inc 's third quarter 2026 Revenue $ 75.25 millions ARWR's Income Statement
Arrowhead Pharmaceuticals Inc 's third quarter 2025 Revenue $ 27.77 millions Quarterly ARWR's Income Statement


ARWR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter September - 823.55 % - 1.71 %
3rd Quarter June 2.05 % -94.88 % - -89.18 %
2nd Quarter March -72.07 % 21608.4 % - 133.84 %
1st Quarter December 2.95 % - -77.95 % 98.07 %
FY (Year on Year)   - 23264.79 % -98.53 % -


Back to ARWR Growth rate Comparisons >> Back to ARWR Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #56
Healthcare Sector #120
Overall #493

Revenue Y/Y Growth Statistics
High Average Low
19736.49 % 1034.93 % -58.55 %
(Sep 30 2017)   (Sep 30 2016)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #56
Healthcare Sector #120
Overall #493
Revenue Y/Y Growth Statistics
High Average Low
19736.49 % 1034.93 % -58.55 %
(Sep 30 2017)   (Sep 30 2016)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Arrowhead Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
21608.36 % 683.56 % -100 %
(Mar 31 2025)  


ARWR's III. Quarter Q/Q Revenue Comment
Arrowhead Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue growth of 2.05% quarter on quarter, to $ 75.25 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -94.88% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Revenue quarter on quarter growth. While Arrowhead Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1407.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #72
Healthcare Sector #194
Overall #1407
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #72
Healthcare Sector #194
Overall #1407
Revenue Q/Q Growth Statistics
High Average Low
21608.36 % 683.56 % -100 %
(Mar 31 2025)  


ARWR's III. Quarter Q/Q Revenue Comment
Arrowhead Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue growth of 2.05% quarter on quarter, to $ 75.25 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -94.88% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Revenue quarter on quarter growth. While Arrowhead Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1407.


Arrowhead Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 669.50 $ 622.01 $ 1,090.98 $ 829.45 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 7.63 % -42.99 % 31.53 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 493 # 410 # 118 # 0 # 0


Cumulative Revenue growth Comment
Arrowhead Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 170.99% year on year, to $ 670 millions if the fiscal year would have ended in Jun 30 2026.
Arrowhead Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Arrowhead Pharmaceuticals Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 7.63 % from $622.01 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at1034.93%.

Arrowhead Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 56
Sector # 120
S&P 500 # 493
Cumulative Revenue growth Comment
Arrowhead Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 170.99% year on year, to $ 670 millions if the fiscal year would have ended in Jun 30 2026.
Arrowhead Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Arrowhead Pharmaceuticals Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 7.63 % from $622.01 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at1034.93%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.63 % increase from $622.01 millions in the period from Mar 31 2026 to Jun 30 2025.

Arrowhead Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 56
Sector # 120
S&P 500 # 493




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARWR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions


About Arrowhead Pharmaceuticals Inc Revenue Growth Rates (ARWR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Arrowhead Pharmaceuticals Inc (CIK 879407).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000879407-26-000057
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Arrowhead Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.